Sign-up now. Access now. Improving Outcomes in the Treatment of Opioid Dependence IOTOD is an educational initiative that aims to improve opioid dependence healthcare through a variety of programmes, such as the annual conference, the THN toolkit, reports and other educational online resources. Founded with the IOTOD conference, an annual event which has been running for 19 years, the IOTOD initiative brings together healthcare professionals from across the globe to share and discuss best practice in the field of opioid dependence. Providing a variety of live and online educational interventions, IOTOD has evolved into a diverse, multiplatform initiative driving change worldwide in the understanding and treatment of opioid dependence. Live expert webinar Holistic treatment for opioid dependence webinar — Monday 21st June BST Register now to watch expert faculty discuss the significance of taking a holistic approach when providing treatment for opioid dependence involving OST Register.
Managing Opioid Addiction with Buprenorphine - American Family Physician
Join NursingCenter to get uninterrupted access to this Article. In this issue of Stories from the Field, two different case studies are presented that center on opioid dependency. Marc was a year-old White male adolescent who was admitted to our treatment facility for heroin abuse. Marc had been transferred from an acute care hospital. I had the pleasure of completing Marc's history and physical examination on admission. Marc's case and story are very interesting.
This addiction case study is a hypothetical example based on our experiences. Diego is a year-old international student living alone while attending undergraduate classes in Boston. He has a long history of poly-substance use disorder, relational trauma, and sexual compulsivity. During his first semester in Boston, he began using oxycontin recreationally and quickly became physically dependent.
Opioid dependence OD may be effectively treated with well-evidenced regimens including psychosocial and pharmacotherapeutic interventions. Treatment has benefits but also limitations including risk of diversion, impact of mandatory daily supervision, and stigma. An injectable prolonged release buprenorphine with flexible dose options has recently been approved by the European Commission and is available in the UK and other European Countries. Initial positive treatment experience in patients with different clinical scenarios patients with no recent treatment history, a transfer from oral methadone, and change from sublingual buprenorphine tablets provides evidence of the potential benefit in a range of situations for this therapeutic option. Adoption of the injectable form was clinically successful with no withdrawal signs, nor evidence of use of other drugs.